News|Articles|November 24, 2025

De-Risking Clinical Development: Strategic Multipliers in Global Trials

Author(s)Seriant

Key Takeaways

  • Personalized treatment strategies have advanced the management of lung cancer brain metastases, integrating targeted therapies and immunotherapies for improved patient outcomes.
  • Stereotactic radiosurgery and whole-brain radiation therapy are evolving with novel systemic therapies, maintaining their importance in treatment plans.
SHOW MORE

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.